Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA2322367
Max Phase: Preclinical
Molecular Formula: C31H33N7O
Molecular Weight: 519.65
Molecule Type: Small molecule
Associated Items:
ID: ALA2322367
Max Phase: Preclinical
Molecular Formula: C31H33N7O
Molecular Weight: 519.65
Molecule Type: Small molecule
Associated Items:
Canonical SMILES: Cc1ccc(C(=O)N2CCC(c3ccc(C#N)cc3)CC2)cc1-c1nc2cc(N3CCN(C)CC3)ncc2[nH]1
Standard InChI: InChI=1S/C31H33N7O/c1-21-3-6-25(31(39)38-11-9-24(10-12-38)23-7-4-22(19-32)5-8-23)17-26(21)30-34-27-18-29(33-20-28(27)35-30)37-15-13-36(2)14-16-37/h3-8,17-18,20,24H,9-16H2,1-2H3,(H,34,35)
Standard InChI Key: FKIWVNDNCVARLD-UHFFFAOYSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: Small molecule | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 519.65 | Molecular Weight (Monoisotopic): 519.2747 | AlogP: 4.58 | #Rotatable Bonds: 4 |
Polar Surface Area: 92.15 | Molecular Species: NEUTRAL | HBA: 6 | HBD: 1 |
#RO5 Violations: 1 | HBA (Lipinski): 8 | HBD (Lipinski): 1 | #RO5 Violations (Lipinski): 1 |
CX Acidic pKa: 11.59 | CX Basic pKa: 7.63 | CX LogP: 4.55 | CX LogD: 4.13 |
Aromatic Rings: 4 | Heavy Atoms: 39 | QED Weighted: 0.42 | Np Likeness Score: -1.57 |
1. Oslob JD, Johnson RJ, Cai H, Feng SQ, Hu L, Kosaka Y, Lai J, Sivaraja M, Tep S, Yang H, Zaharia CA, Evanchik MJ, McDowell RS.. (2013) Imidazopyridine-Based Fatty Acid Synthase Inhibitors That Show Anti-HCV Activity and in Vivo Target Modulation., 4 (1): [PMID:24900571] [10.1021/ml300335r] |
2. (2014) Heterocyclic modulators of lipid synthesis, |
Source(2):